We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alligator Bioscience Ab | LSE:0RK9 | London | Ordinary Share | SE0000767188 | ALLIGATOR BIOSCIENCE ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 59.27M | -248.59M | -0.3778 | -60.88 | 15.13B |
STOCKHOLM, Oct. 21, 2021 /PRNewswire/ -- First Patient Dosed in Optimize-1 Phase II
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer. We entered a collaboration with Finnish based Orion Corporation focusing on the discovery of novel immuno-oncology product candidates. With my first full quarter at the helm of this amazing company, I am even more confident in the potential value of our robust pipeline."
Søren Bregenholt
CEO Alligator Bioscience AB (publ)
Significant Events: July – September 2021
FINANCIAL SUMMARY
July-September 2021
January-September 2021
The full report is attached as PDF available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/
Conference call/webcast
Alligator will host a conference call today, October 21, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Marie Svensson will present and comment on the Interim Report. The conference call will be held in English.
The conference call will be broadcast live on the web via the link: https://financialhearings.com/event/13657
Telephone number for the conference call is:
SE: +46856642692
UK: +443333009260
US: +1 6319131422
PIN US: 47085846#
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 a.m. CEST on October 21, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Outlicensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--interim-report-january-september-2021,c3437219
The following files are available for download:
https://mb.cision.com/Main/12681/3437219/1483944.pdf | Alligator Bioscience AB: Interim report Januaryâ€"September 2021 (PDF) |
https://mb.cision.com/Public/12681/3437219/920ca2f2bcccaf30.pdf | Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/alligator-bioscience-ab-interim-report-januaryseptember-2021-301405432.html
SOURCE Alligator Bioscience
Copyright 2021 PR Newswire
1 Year Alligator Bioscience Ab Chart |
1 Month Alligator Bioscience Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions